UnitedHealth Group (UNH) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is cautiously constructive — consensus has been reset lower since Q1’s beat, but the bar is still not easy given a structurally elevated MCR in Q2 and a back-half-weighted earnings drag; the single biggest swing factor is whether the operating MCR comes in at or below the ~88.5% consensus estimate.

UNH heads into Q2 2026 earnings with a meaningfully lower bar than a quarter ago, but not a trivially easy one. Consensus operating EPS sits at $4.87 — down sharply from Q1’s $7.23 print — reflecting management’s own guidance that UnitedHealthcare earnings are over 75% weighted to the first half and that OptumHealth’s profitability will moderate materially from Q1 levels.

Management’s tone on the Q1 call was constructive but deliberately patient: the FY2026 adjusted EPS guidance was raised to

greater than $18.25 (from prior guidance), yet the cadence language — “2/3 of earnings in the first half, 1/3 in the second half” — implies Q2 operating EPS in the $4.50–$5.00 range, broadly in line with the $4.87 consensus. Estimate revisions have been modestly negative since the Q1 print, with the Q2 consensus drifting from ~$4.82 (as of April 28) to $4.87 today, suggesting the street has largely digested the cadence guidance.

The stock has rallied ~21% since the Q1 print (vs. +7.2% for SPY and +8.5% for XLV), recovering from its early-2026 lows, which means some beat is already priced in and the stock is not a low-expectations setup.

The key wildcard is medical cost trend in Medicare Advantage: management priced 2026 MA at ~10% trend vs. a historical 7–8%, and Q1 showed early signs of pricing-trend alignment — if Q2 MA utilization remains benign (as ELV’s Q2 print today suggested for its own MA book), UNH could surprise positively on MCR; conversely, any re-acceleration in outpatient surgery, behavioral health, or specialty pharmacy costs — the exact categories ELV flagged as “elevated and concentrated” — would pressure the MCR and likely disappoint.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a moderate bar on operating EPS ($4.87) and a slightly easier bar on MCR (88.5% vs. Q1’s 83.9% actual), reflecting the known seasonal step-up; the bigger swing factor is OptumHealth’s operating income, which beat dramatically in Q1 but is expected to moderate sharply in Q2.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 15, 2026. Q2 2026 actuals not yet reported.

Table 2 — Beat / Miss History (Last 8 Quarters)

Top KPI 1: Operating EPS | Top KPI 2: Medical Loss Ratio — Operating (%)

Pattern: UNH has beaten on operating EPS in 5 of the last 8 quarters, but the MCR has been a persistent source of negative surprise — missing in 4 of 8 quarters — with the notable exception of Q1 2026 and Q1 2025 where favorable reserve development and lower respiratory activity drove meaningful MCR beats. Q2 2025 was the worst quarter in recent memory (EPS miss of ~12%), making the year-ago comparison relatively easy on EPS but the MCR bar is still demanding.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management’s tone has shifted from cautiously optimistic (Q1 2026 beat) to deliberately patient — the FY guidance raise to >$18.25 was constructive, but the explicit H1/H2 cadence warning and the OptumHealth moderation language set a lower Q2 bar; the most important evolution since Q1 is the more collaborative posture on 2027 MA rates and the accelerated OptumHealth margin recovery narrative.

Sources: UNH Q1 2026 Earnings Call Transcript (April 21, 2026); UNH 8-K / BofA Securities Health Care Conference (May 12, 2026).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimate revisions have been modestly positive since the Q1 beat — the Q2 operating EPS consensus moved from $4.82 (as of April 28, the first post-earnings snapshot) to $4.87 today, a ~+1% drift upward, suggesting the street has absorbed the cadence guidance and is not aggressively cutting numbers into the print.

Source: Visible Alpha Consensus and Actuals Data. Pre-Q1 earnings snapshot as of April 28, 2026; current as of July 15, 2026.

5. Stock Performance

Key Takeaway: UNH has outperformed both the S&P 500 and the healthcare sector by a wide margin since the Q1 2026 earnings beat, rallying +21.0% vs. +7.2% for SPY and +8.5% for XLV — the stock is no longer a low-expectations setup, and some beat is already priced in heading into Q2.

UNH vs. XLV (Health Care ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings (Apr 21, 2026). Source: Stock Price Data.

Performance Summary (Apr 21 – Jul 15, 2026):

• UNH: +21.0% ($346.01 → $418.52)
• XLV (Health Care ETF): +8.5%
• SPY (S&P 500): +7.2%
• UNH vs. XLV alpha: +12.5 ppts
• UNH vs. SPY alpha: +13.8 ppts

Key Observations:

• The stock gapped up ~6% on April 21 (Q1 earnings day) and continued to grind higher through mid-May, aided by the BofA Healthcare Conference on May 12 where management articulated an expanded AI vision and reaffirmed the long-term 13–16% EPS growth algorithm.
• A modest pullback in late May/early June was followed by a sharp re-rating in mid-June, with UNH reaching ~$427 on June 26 before settling back to ~$418 today.
• At $418.52, UNH trades at approximately 22.6x FY2026 consensus operating EPS of $18.51 — a premium to the managed care peer group average but below UNH’s own 5-year historical NTM P/E range of 20–25x, suggesting the multiple is not stretched but also not cheap.
• The stock’s outperformance means the market has already rewarded the Q1 beat and the guidance raise; a Q2 in-line print may not be enough to sustain the rally, and a miss on MCR could trigger a meaningful reversal.

Source: Stock Price Data.

6. Peer Commentaries — Read-Through for UNH Q2 2026

Key Takeaway: Peer commentary since UNH’s Q1 2026 earnings (April 21) is broadly constructive for UNH’s Q2 setup — Humana’s MA utilization is tracking in-line-to-better, Centene’s Medicaid cost drivers are identifiable and actionable, and ELV’s Q2 2026 print today (July 15) showed favorable MA and ACA benefit expense performance — all of which are positive read-throughs for UNH’s MCR. The key risk flagged across all peers is that cost drivers (behavioral health, specialty pharmacy, outpatient surgery, ED utilization) remain elevated and concentrated, and the funding gap in MA persists into 2027.

Note: Only commentary from Q1 2026 earnings calls (reported after April 21, 2026) and ELV’s Q2 2026 earnings call (July 15, 2026) are included below. Prior-quarter results commentary has been excluded.

6.1 Elevance Health (ELV) — Q2 2026 Earnings (July 15, 2026)

Read-Through Signal: POSITIVE for UNH MCR and MA profitability

ELV reported Q2 2026 adjusted EPS of $7.45, exceeding its own outlook, driven by favorable benefit expense performance in Medicare Advantage and individual ACA. This is the most direct and timely read-through for UNH, as both companies face the same MA cost environment in Q2 2026.

• MA & ACA favorability: ELV cited “favorable benefit expense performance in Medicare Advantage and individual ACA” as the primary driver of the Q2 beat — a direct positive read-through for UNH’s MA MCR.
• Cost drivers remain elevated but concentrated: ELV flagged behavioral health, specialty pharmacy, outpatient surgery, and ED utilization as the key elevated cost categories — consistent with UNH’s own Q1 commentary. Importantly, ELV stated these drivers are “identifiable and actionable,” suggesting no new stepwise acuity reset.
• Medicaid in-line: ELV’s Q2 Medicaid cost trend “developed broadly in line with expectations” — positive for UNH’s Medicaid book, though UNH’s Medicaid exposure is smaller relative to ELV.
• No new acuity reset: ELV explicitly stated it is “not observing a new stepwise acuity reset” in Medicaid — the post-PHE unwinding dynamic is moderating, which reduces tail risk for UNH.
• Investment income one-time: ELV recorded a $0.80/share below-the-line benefit from investment income valuation adjustments, which it intends to deploy into one-time H2 investments. This is ELV-specific and not a read-through for UNH.
• Outlook: ELV’s 2026 outlook assumes the elevated cost environment “persists through the balance of the year” — a cautious but not deteriorating signal for UNH’s H2 MCR guidance.

6.2 Humana (HUM) — Q1 2026 Earnings (April 29, 2026)

Read-Through Signal: POSITIVE for UNH MA utilization and MCR

Humana reported Q1 2026 results “where we expected to be,” with MA members (both new and existing) performing “in-line to better than guidance.” April data was consistent with Q1 observations — a constructive forward signal for UNH’s Q2 MA utilization.

• MA utilization tracking well: Key indicators including risk scores, hospital admits per thousand, pharmacy claims, and initial medical claims were “running in line to better than expectations.” This is a positive read-through for UNH’s MA book heading into Q2.
• Q2 MLR guided slightly above 91%: Humana guided Q2 2026 MLR to be “slightly above 91%” — a seasonal step-up from Q1, consistent with UNH’s own cadence guidance that H1 MCR will be >250 bps below the FY midpoint.
• MA trend stable for 2 years: Humana noted that “medical cost trend has been relatively stable now for 2 years,” though it continues to outpace program funding. The gap between funding and trend is “larger going into this bid season than a year ago” — a structural concern for 2027 MA pricing that UNH has also flagged.
• PPO repricing complete: After “2 years repricing our PPO product,” Humana sees growth rebalancing back to HMO/PPO parity — a positive signal that the industry’s aggressive repricing cycle is working, which supports UNH’s own MA margin recovery thesis.
• 2026 goal: double individual MA margin: Humana expects to “double individual MA margin in 2026 adjusted for Stars” and return to a sustainable 3%+ margin by 2028 — consistent with the broader industry repricing narrative that underpins UNH’s own margin recovery story.

6.3 Centene (CNC) — Q1 2026 Earnings (April 28, 2026)

Read-Through Signal: MIXED — Medicaid cost drivers elevated but manageable; commercial and MA more constructive

Centene’s Q1 2026 commentary is most relevant for UNH’s Medicaid segment, where both companies face similar post-PHE unwinding dynamics and elevated behavioral health costs.

• Medicaid cost drivers elevated but identifiable: Centene flagged behavioral health (including ABA therapy), ED utilization, outpatient surgery, and specialty pharmacy as the primary Medicaid cost drivers — exactly the same categories UNH and ELV have cited. The consistency across peers suggests these are industry-wide, not company-specific, issues.
• No new stepwise acuity reset: Like ELV, Centene noted it is not seeing a new stepwise acuity reset in Medicaid — the post-PHE dynamic is moderating, which is a positive read-through for UNH’s Medicaid MCR.
• Medicaid redeterminations ongoing: Members leaving Medicaid are still lower-cost than those staying, but the gap has “significantly narrowed” — suggesting the worst of the acuity headwind is behind the industry.
• Outpatient surgery not universal: Centene noted outpatient surgery is “not a universal trend driver but is relevant in certain lines of business” — a nuanced signal that UNH’s exposure may vary by segment.

6.4 CVS Health (CVS) — Q1 2026 Earnings (May 6, 2026)

Read-Through Signal: MIXED — Aetna MA and commercial trends relevant; PBM dynamics a watch item for OptumRx

CVS’s Q1 2026 commentary is relevant for UNH on two dimensions: (1) Aetna’s MA and commercial health plan trends as a read-through for UNH’s insurance segment, and (2) CVS Caremark’s PBM dynamics as a read-through for OptumRx.

• MA cost environment consistent with peers: CVS/Aetna’s MA commentary was broadly consistent with Humana and ELV — elevated but stable trends, with repricing actions beginning to take hold. No incremental negative surprise relative to what UNH has already guided.
• PBM competitive dynamics: CVS Caremark’s commentary on the PBM competitive landscape is relevant for OptumRx, which is transitioning to a transparent fee-based model. CVS’s experience with similar transparency initiatives will be a useful benchmark for whether OptumRx’s margin-neutral transition thesis holds.
• Specialty pharmacy cost pressure: CVS flagged specialty pharmacy (including GLP-1s) as a persistent cost driver across its health plan and PBM businesses — consistent with UNH’s own commentary and a watch item for UNH’s Q2 MCR.

6.5 Cigna (CI) — Q1 2026 Earnings (April 30, 2026) & BofA Conference (May 13, 2026)

Read-Through Signal: POSITIVE for commercial health trends; limited MA read-through (CI exited MA)

Cigna’s commentary is most relevant for UNH’s commercial insurance segment (Evernorth/PBM and commercial health benefits), as Cigna exited the Medicare Advantage market.

• Commercial health trends stable: Cigna’s commercial health benefits commentary was constructive — utilization trends broadly in line with expectations, with no incremental deterioration in the commercial book. This is a positive read-through for UNH’s commercial risk-based membership MCR.
• Evernorth / PBM growth: Cigna’s Evernorth platform (PBM + specialty pharmacy) continued to grow, with management highlighting specialty pharmacy and biosimilar adoption as key growth drivers. This is relevant context for OptumRx’s competitive positioning and the broader PBM market dynamics.
• No MA exposure: Cigna’s exit from Medicare Advantage means its Q2 commentary will not provide a direct MA read-through for UNH — ELV and Humana remain the primary MA read-through peers.

Peer Read-Through Summary Table

7. Material News & Developments (Since Q1 2026 Earnings)

Key Takeaway: The most important post-Q1 development is the final 2027 MA rate notice, which management characterized as better than the proposed rate — a constructive shift that reduces near-term regulatory overhang, though the fundamental funding gap vs. medical cost trend persists.

• 2027 Medicare Advantage Final Rate Notice (post-Q1): Management explicitly thanked the Trump administration for better aligning 2027 MA funding with healthcare cost increases in the final rate notice. While the widely expected medical trend for 2027 still meaningfully exceeds funding levels, the tone shifted from “disappointed-but-constructive” to “cautiously appreciative.” This reduces the risk of a sharp 2027 MA membership exit and supports UNH’s multi-year margin recovery narrative.
• BofA Securities Health Care Conference (May 12, 2026): Senior UNH leaders presented at the BofA conference, reaffirming the 13–16% long-term EPS growth algorithm and articulating an expanded AI vision. Key new disclosures included: (1) OptumHealth ahead of schedule on margin recovery, (2) ambient listening enabling auto-coding and auto-adjudication in clinics, (3) Alegeus positioned as a white-label HSA/payment platform, and (4) Optimize AI consulting arm signing initial contracts.
• OptumRx Transparent PBM Model Transition: Management is transitioning OptumRx to a fee-based per-member monthly pricing model, eliminating spread pricing and providing full GPO fee disclosure. The transition is expected to be margin-neutral within the existing margin range, with group purchasing transitioning to flat service fees by end of 2027. This is a proactive response to regulatory and public pressure on PBM practices.
• AI Investment Ramp ($1.5B in 2026): UNH disclosed approximately $1.5B in 2026 AI investment, with ~1/3 directed to Optum Insight product development and ~2/3 to enterprise processes. Management expects a conservative 2:1 return on internal AI programs over the next few years, with many paying back within 12–18 months. Aviary (generative AI chatbot) has scaled to 20M+ members; Optum Real has processed 500M+ transactions YTD.
• Insider Transaction — Optum CEO Share Sale (April 23, 2026): Patrick Hugh Conway, CEO of Optum, sold 800 shares of UNH common stock on April 23, 2026 (filed April 27), at market prices. The sale was not under a 10b5-1 plan. Conway retained 17,804 shares post-transaction. The sale is small relative to his total holdings and is not considered a material negative signal.
• Q2 2026 Earnings Confirmed for July 16, 2026: UNH confirmed Q2 2026 results will be released before market open on July 16, 2026, with a conference call at 8:00 a.m. ET.

8. Insider Transaction Activity

Key Takeaway: The only notable insider transaction since Q1 earnings was a small open-market sale by the Optum CEO — not under a 10b5-1 plan, but immaterial relative to total holdings and not a meaningful negative signal.

Source: SEC Form 4 Filing — Conway Patrick Hugh (UNH), filed April 27, 2026.

Commentary: The sale of 800 shares (~4.3% of Conway’s post-transaction holdings of 17,805 shares) is a routine, small-scale transaction. The absence of a 10b5-1 plan is worth noting but is not unusual for executives making modest portfolio adjustments. No other insider transactions were identified in the post-Q1 earnings window (April 21 – July 15, 2026). The lack of insider buying at current price levels (~$418) is neutral — not a negative signal given the stock’s 21% rally since Q1 earnings.

Appendix: Key Risks & Considerations

Upside Risks:

• MCR beats consensus: If MA utilization remains benign in Q2 (as ELV’s Q2 print suggests), UNH’s operating MCR could come in below the 88.5% consensus, driving an EPS beat similar to Q1 2026.
• OptumHealth upside: OptumHealth beat dramatically in Q1 ($1.31B vs. $441M consensus); even a modest beat vs. the $532M Q2 consensus would be a positive catalyst.
• Favorable reserve development: Q1 2026 benefited from >$500M in net favorable prior-period reserve development; any continuation of this pattern in Q2 would be additive to EPS.
• 2027 MA rate environment improving: The final 2027 MA rate notice was better than the proposed rate; any further positive CMS actions could re-rate the stock.

Downside Risks:

• MCR re-acceleration: If behavioral health, specialty pharmacy, or outpatient surgery costs accelerate beyond Q1 levels in Q2, the MCR could exceed the 88.5% consensus, repeating the Q2 2025 miss pattern.
• OptumHealth moderation worse than guided: Management guided for a “significant majority” of OptumHealth’s FY earnings in H1; if Q2 comes in below the $532M consensus, it would raise questions about the 2026 margin recovery trajectory.
• MA membership attrition: If MA membership declines faster than the guided ~−1.3M from year-end 2025, it would signal competitive pressure beyond what management has acknowledged.
• 2027 MA funding gap: Despite the improved final rate notice, the widely expected 2027 MA medical cost trend still meaningfully exceeds funding levels — a structural headwind that could weigh on 2027 guidance when issued.
• Regulatory / legal overhang: Ongoing investigations, prior authorization scrutiny, and reputational damage from the cyberattack remain background risks that could resurface as headline risk around the earnings print.

Disclaimer: This document is prepared for informational purposes only and is based on publicly available information and consensus data as of July 15, 2026. It does not constitute investment advice.